

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that

10/554, 186

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:14:58 ON 12 APR 2007

FILE 'REGISTRY' ENTERED AT 16:15:08 ON 12 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 APR 2007 HIGHEST RN 929721-97-1
DICTIONARY FILE UPDATES: 11 APR 2007 HIGHEST RN 929721-97-1

New CAS Information Use Policies, enter HELP USAGETERMS for details

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10554186.str



```

chain nodes :
21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 22 23 24 25 26
chain bonds :
5-7 6-8 21-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-9 7-13 8-14 8-18 9-10 10-11 11-12 12-13
14-15 15-16 16-17 17-18 22-23 22-26 23-24 24-25 25-26
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-8 21-22 22-23 22-26 23-24 24-25 25-26
normalized bonds :
7-9 7-13 8-14 8-18 9-10 10-11 11-12 12-13 14-15 15-16 16-17 17-18

```

G1:C,N

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom

```


10/554,186

=> d 11

L1 HAS NO ANSWERS

L1

STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam

SAMPLE SEARCH INITIATED 16:15:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2117 TO ITERATE

94.5% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 39580 TO 45100
PROJECTED ANSWERS: 2 TO 129


L2 2 SEA SSS SAM L1

=> d scan


10/554, 186

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[1-[[4-(3-phenyl-2-
quinoxalinyl)phenyl]methyl]-2-pyrrolidinyl]-, trifluoroacetate (9CI)
MF C27 H24 N6 O . x C2 H F3 O2

CM 1




CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[(3R)-3-[(5-
thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]- (9CI)
MF C30 H25 N5 O3 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10/554,186

=> s 11 sss ful
FULL SEARCH INITIATED 16:15:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 41643 TO ITERATE

100.0% PROCESSED 41643 ITERATIONS 47 ANSWERS
SEARCH TIME: 00.00.01

L3 47 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
172.10 172.31

FILE 'CAPLUS' ENTERED AT 16:15:52 ON 12 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Apr 2007 VOL 146 ISS 16
FILE LAST UPDATED: 11 Apr 2007 (20070411/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 9 L3


=> d 14 1-9 bib hitstr

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:433750 CAPLUS
 DN 141:7131
 TI Preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for the treatment of cancer
 IN Barnett, Stanley F.; Defeo-Jones, Deborah D.; Hartman, George D.; Huber, Hans E.; Stirdivant, Steven M.; Heimbrook, David C.
 PA USA
 SO U.S. Pat. Appl. Publ., 121 pp., which
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004102360	A1	20040527	US 2003-678565	20031003
PRAI US 2002-422312P	P	20021030		
US 2003-460911P	P	20030407		
OS MARPAT 141:7131				
IT 612847-47-9P	612847-51-5P	612847-52-6P		
612847-53-7P	612847-55-9P	612847-57-1P		
612847-59-3P	612847-61-7P	612847-62-8P		
612847-63-9P	612847-65-1P	612847-67-3P		
612847-85-5P	612847-89-9P	612847-91-3P		
612847-93-5P	612847-95-7P	612847-97-9P		
612848-67-6P	616870-54-3P			
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(antitumor agent; preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for treatment of cancer)				
RN 612847-47-9	CAPLUS			
CN Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)				


CM 1

CRN 612847-46-8
 CMF C33 H28 N4



CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 612847-51-5 CAPLUS


CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-50-4

CMF C32 H26 Cl2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-52-6 CAPLUS

CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-53-7 CAPLUS


CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-52-6

CMF C33 H27 N5 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-55-9 CAPLUS


CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-54-8

CMF C33 H27 F3 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-57-1 CAPLUS


CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-56-0

CMF C32 H26 F2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-59-3 CAPLUS


CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-58-2

CMF C32 H26 F2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-61-7 CAPLUS


CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-60-6

CMF C32 H26 F2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-62-8 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-63-9 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-62-8

CMF C29 H25 N5 O S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 612847-65-1 CAPLUS
 CN 4-Thiazolecarboxamide, N-[(3R)-1-[(4-(3-phenyl-2-quinoxalinyl)phenyl)methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-64-0
CMF C29 H25 N5 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-67-3 CAPLUS


CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-66-2

CMF C29 H29 N5 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-85-5 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-84-4

CMF C29 H26 N6 O S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 612847-89-9 CAPLUS
 CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-88-8
CMF C30 H25 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-91-3 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-90-2

CMF C28 H24 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-93-5 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-92-4


CMF C28 H24 N6 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-95-7 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[(4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl)methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-94-6
CMF C28 H24 N6 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-97-9 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-96-8


CMF C29 H25 N5 O2 S

Absolute stereochemistry.

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612848-67-6 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-66-5


CMF C30 H25 N7 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616870-54-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-86-6
CMF C30 H25 N5 O3 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:836857 CAPLUS
 DN 139:350755
 TI Preparation of fused quinoxaline derivatives as inhibitors of Akt activity for treating cancer
 IN Lindsley, Craig W.; Zhao, Zhijian
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086404	A1	20031023	WO 2003-US10447	20030404
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2481241	A1	20031023	CA 2003-2481241	20030404
	AU 2003226271	A1	20031027	AU 2003-226271	20030404
	EP 1494676	A1	20050112	EP 2003-746610	20030404
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005159422	A1	20050721	US 2003-510066	20030404
	JP 2005528394	T	20050922	JP 2003-583423	20030404
PRAI	US 2002-370833P	P	20020408		
	US 2002-417411P	P	20021009		
	WO 2003-US10447	W	20030404		
OS	MARPAT 139:350755				
IT	612848-66-5P 612848-67-6P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of fused quinoxaline derivs. as inhibitors of Akt activity for treating cancer)				
RN	612848-66-5 CAPLUS				
CN	5-Thiazolecarboxamide, N-[(3R)-1-[(4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)phenyl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 612848-67-6 CAPLUS

10/554,186


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-66-5

CMF C30 H25 N7 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:836856 CAPLUS

DN 139:337991

TI Preparation of N-[4-(3-phenylquinoxalin-2-yl)benzyl] substituted sulfonamides as inhibitors of Akt activity

IN Lindsley, Craig W.; Zhao, Zhijian

PA Merck & Co., Inc., USA

SO PCT Int.. Appl., 101 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086403	A1	20031023	WO 2003-US10341	20030404
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2480880	A1	20031023	CA 2003-2480880	20030404
	AU 2003230802	A1	20031027	AU 2003-230802	20030404
	EP 1496906	A1	20050119	EP 2003-723899	20030404
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005130977	A1	20050616	US 2003-510067	20030404
	JP 2005530726	T	20051013	JP 2003-583422	20030404
PRAI	US 2002-370846P	P	20020408		
	WO 2003-US10341	W	20030404		
OS	MARPAT 139:337991				
IT	616224-52-3P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of N-[4-(3-phenylquinoxalin-2-yl)benzyl] substituted sulfonamides as inhibitors of Akt activity for treating cancer)				
RN	616224-52-3 CAPLUS				
CN	1H-Isoindole-1,3(2H)-dione, 2-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-(9CI) (CA INDEX NAME)				



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:836848 CAPLUS
 DN 139:350754
 TI Preparation of 2,3-diphenylquinoxaline derivatives as inhibitors of Akt activity for treating cancer
 IN Bilodeau, Mark T.; Duggan, Mark E.; Hartnett, John C.; Lindsley, Craig W.; Manley, Peter J.; Wu, Zhicai; Zhao, Zhiqian
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 228 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086394	A1	20031023	WO 2003-US10442	20030404
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2480800	A1	20031023	CA 2003-2480800	20030404
	AU 2003223467	A1	20031027	AU 2003-223467	20030404
	EP 1496896	A1	20050119	EP 2003-719597	20030404
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005533010	T	20051104	JP 2003-583413	20030404
	US 2005222155	A1	20051006	US 2004-510069	20041004
PRAI	US 2002-370847P	P	20020408		
	US 2002-417174P	P	20021009		
	WO 2003-US10442	W	20030404		
OS	MARPAT 139:350754				
IT	612847-46-8P 612847-47-9P 612847-50-4P 612847-51-5P 612847-52-6P 612847-53-7P 612847-54-8P 612847-55-9P 612847-56-0P 612847-57-1P 612847-58-2P 612847-59-3P 612847-60-6P 612847-61-7P 612847-62-8P 612847-63-9P 612847-64-0P 612847-65-1P 612847-66-2P 612847-67-3P 612847-84-4P 612847-85-5P 612847-86-6P 612847-88-8P 612847-89-9P 612847-90-2P 612847-91-3P 612847-92-4P 612847-93-5P 612847-94-6P 612847-95-7P 612847-96-8P 612847-97-9P 616868-00-9P 616870-54-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 2,3-diphenylquinoxaline derivs. as inhibitors of Akt activity for treating cancer)				
RN	612847-46-8 CAPLUS				
CN	Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)				




RN 612847-47-9 CAPLUS

CN Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-46-8


CMF C33 H28 N4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-50-4 CAPLUS

CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-51-5 CAPLUS


CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-50-4

CMF C32 H26 Cl2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-52-6 CAPLUS

CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/554,186

RN 612847-53-7 CAPLUS


CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-52-6

CMF C33 H27 N5 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-54-8 CAPLUS

CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-55-9 CAPLUS

CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-54-8
 CMF C33 H27 F3 N4 O

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 612847-56-0 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-57-1 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

10/554,186


CRN 612847-56-0
CMF C32 H26 F2 N4 O

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-58-2 CAPLUS
CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-59-3 CAPLUS
CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-58-2

10/554,186

CMF C32 H26 F2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-60-6 CAPLUS

CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-61-7 CAPLUS


CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

10/554,186


CRN 612847-60-6
CMF C32 H26 F2 N4 O

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-62-8 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-63-9 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-62-8
CMF C29 H25 N5 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-64-0 CAPLUS
CN 4-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-65-1 CAPLUS
CN 4-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-64-0
CMF C29 H25 N5 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 612847-66-2 CAPLUS
 CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-67-3 CAPLUS
 CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-66-2
CMF C29 H29 N5 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-84-4 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-85-5 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-84-4
CMF C29 H26 N6 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-86-6 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-88-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-89-9 CAPLUS


CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-88-8

CMF C30 H25 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-90-2 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-91-3 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[(4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl)methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-90-2

CMF C28 H24 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-92-4 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[(4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-93-5 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-92-4


CMF C₂₈ H₂₄ N₆ O S

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C₂ H F₃ O₂

RN 612847-94-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-95-7 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-94-6

CMF C28 H24 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-96-8 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-97-9 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-96-8

CMF C29 H25 N5 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 616868-00-9 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-2-pyrrolidinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


10/554, 186

CRN 616867-99-3
CMF C27 H24 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616870-54-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-86-6
CMF C30 H25 N5 O3 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

10/554,186


CMF C2 H F3 O2




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:818232 CAPLUS
 DN 139:323527
 TI Preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer
 IN Barnett, Stanley F.; Defeo-Jones, Deborah; Haskell, Kathleen M.; Huber, Hans E.; Nahas, Deborah D.; Lindsley, Craig W.; Zhao, Zhijian; Hartman, George D.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 170 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084473	A2	20031016	WO 2003-US10632	20030404
	WO 2003084473	A3	20040212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003226301	A1	20031020	AU 2003-226301	20030404
	US 2006142178	A1	20060629	US 2004-510068	20041004
PRAI	US 2002-370827P	P	20020408		
	US 2002-417202P	P	20021009		
	WO 2003-US10632	W	20030404		
IT	612847-47-9P	612847-51-5P	612847-53-7P		
	612847-55-9P	612847-57-1P	612847-59-3P		
	612847-61-7P	612847-63-9P	612847-65-1P		
	612847-67-3P	612847-85-5P	612847-87-7P		
	612847-89-9P	612847-91-3P	612847-93-5P		
	612847-95-7P	612847-97-9P	612848-67-6P		
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)	(preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer)			
RN	612847-47-9 CAPLUS				
CN	Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)				
CM	1				
CRN	612847-46-8				
CMF	C33 H28 N4				



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 612847-51-5 CAPLUS
 CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-50-4
CMF C32 H26 Cl2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 612847-53-7 CAPLUS
 CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

10/554, 186


CRN 612847-52-6
CMF C33 H27 N5 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-55-9 CAPLUS

CN Benzamide, N-[(3R)-1-[(4-(3-phenyl-2-quinoxalinyl)phenyl)methyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-54-8
CMF C33 H27 F3 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 612847-57-1 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-56-0
 CMF C32 H26 F2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 612847-59-3 CAPLUS
 CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-58-2
 CMF C32 H26 F2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-61-7 CAPLUS

CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-
quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA
INDEX NAME)

CM 1

CRN 612847-60-6
CMF C32 H26 F2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-63-9 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-62-8

CMF C29 H25 N5 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-65-1 CAPLUS


CN 4-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-64-0

CMF C29 H25 N5 O S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 612847-67-3 CAPLUS
 CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-66-2
CMF C29 H29 N5 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-85-5 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-84-4

CMF C29 H26 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-87-7 CAPLUS


CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-86-6


CMF C30 H25 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-89-9 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[[3R]-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-88-8
CMF C30 H25 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-91-3 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-90-2

CMF C28 H24 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-93-5 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-92-4

CMF C28 H24 N6 O S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 612847-95-7 CAPLUS
 CN 5-Thiazolecarboxamide, N-[(3R)-1-[(4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl)methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-94-6
CMF C28 H24 N6 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-97-9 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-96-8

CMF C29 H25 N5 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612848-67-6 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-66-5


CMF C30 H25 N7 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1993:517279 CAPLUS
 DN 119:117279
 TI A process for the preparation of thieno[4,5-g] quinoxaline amebicides
 IN Venugopalan, Bindumadhavan; Bapat, Chintamani Prabhakar; Chatterjee,
 Deepak Kumar; De Souza, Noel John; Rupp, Richard Helmut
 PA Hoechst India Ltd., India
 SO Indian, 26 pp.
 CODEN: INXXAP
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IN 167425	A1	19901027	IN 1988-BO46	19880226
PRAI	IN 1988-BO46		19880226		
OS	MARPAT 119:117279				
IT	127692-48-2P 149397-06-8P			RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and amebicidal activity of)	
RN	127692-48-2 CAPLUS				
CN	Pyrrolidine, 1-[[5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]thieno[2,3-g]quinoxalin-7-yl]carbonyl]- (9CI) (CA INDEX NAME)				



RN 149397-06-8 CAPLUS
 CN Thieno[2,3-g]quinoxaline-7-carboxylic acid, 5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 127692-35-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and hydrolysis of, in amebicide preparation)
 RN 127692-35-7 CAPLUS
 CN Thieno[2,3-g]quinoxaline-7-carboxylic acid, 5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1992:41482 CAPLUS
 DN 116:41482
 TI Preparation of 5,8-dimethoxy-2,3-bis(4-aminomethylphenyl)quinoxalines as protozoacides
 IN Venugopalan, Bindumadhavan; Chatterjee, Deepak Kumar; De Souze, Noel John;
 Rupp, Richard Helmut
 PA Hoechst India Ltd., India
 SO Indian, 17 pp.
 CODEN: INXXAP
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IN 166761	A1	19900714	IN 1987-BO125	19870410
PRAI IN 1987-BO125		19870410		
OS MARPAT 116:41482				
IT 136270-45-6P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation, as protozoacide)				
RN 136270-45-6 CAPLUS				
CN Quinoxaline, 5,8-dimethoxy-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)				




L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1991:559095 CAPLUS
 DN 115:159095
 TI Synthesis and antiamoebic activity of 2,3-diaryl-5,8-dimethoxyquinoxalines
 AU Venugopalan, B.; Sureshi, S.; Karnik, P. J.; De Souza, N. J.; Chatterjee, D. K.; Iyer, S. N.
 CS Dep. Chem., Hoechst Indian Ltd., Bombay, 400 080, India
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1991), 30B(8), 777-83
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 IT 136270-45-6P 137389-47-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antiamoebic activity of)
 RN 136270-45-6 CAPLUS
 CN Quinoxaline, 5,8-dimethoxy-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI)
 (CA INDEX NAME)




RN 137389-47-0 CAPLUS
 CN Quinoxaline, 6,7-dimethoxy-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI)
 (CA INDEX NAME)




L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1990:423849 CAPLUS
 DN 113:23849
 TI Synthesis of thieno[3,2-g]quinoxalines as potential amebicides
 AU Venugopalan, B.; Bapat, C. P.; De Souza, N. J.; Chatterjee, D. K.; Iyer, N. J.
 CS Res. Cent., Hoechst India Ltd., Bombay, 400080, India
 SO European Journal of Medicinal Chemistry (1989), 24(6), 611-14
 CODEN: EJMCA5; ISSN: 0223-5234
 DT Journal
 LA English
 OS CASREACT 113:23849
 IT 127692-35-7P 127692-48-2P 127692-49-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and amebicide activity of)
 RN 127692-35-7 CAPLUS
 CN Thieno[2,3-g]quinoxaline-7-carboxylic acid, 5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 127692-48-2 CAPLUS
 CN Pyrrolidine, 1-[(5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]thieno[2,3-g]quinoxalin-7-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 127692-49-3 CAPLUS
 CN Piperidine, 1-[(5,9-dimethoxy-8-methyl-2,3-bis[4-(1-piperidinylmethyl)phenyl]thieno[2,3-g]quinoxalin-7-yl]carbonyl]- (9CI) (CA INDEX NAME)



10/554,186

=> log y
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	33.05	205.36

STN INTERNATIONAL LOGOFF AT 16:16:21 ON 12 APR 2007

10/554, 186

Welcome to STN International! Enter x:x

LOGINID: ssspta1611bxv

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:59:56 ON 03 OCT 2004

=> file reg
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:00:10 ON 03 OCT 2004

10/554,186

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2004 HIGHEST RN 755753-81-2
DICTIONARY FILE UPDATES: 1 OCT 2004 HIGHEST RN 755753-81-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END) :end

=>
Uploading C:\STNEXP4\QUERIES\504012157.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d l1
L1 HAS NO ANSWERS
L1 STR
/ Structure 1 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 12:00:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 375 TO ITERATE

100.0% PROCESSED 375 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6339 TO 8661
PROJECTED ANSWERS: 1 TO 80

L3 1 SEA SSS SAM L1

=> d scan

10/554,186

L3 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI)
MF C33 H35 N5 O2 . x C2 H F3 O2

CM 1

/ Structure 2 in file .gra /

CM 2

/ Structure 3 in file .gra /

ALL ANSWERS HAVE BEEN SCANNED

10/554,186

=> s 11 sss ful
FULL SEARCH INITIATED 12:00:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7252 TO ITERATE

100.0% PROCESSED 7252 ITERATIONS
SEARCH TIME: 00.00.01

33 ANSWERS

L4 33 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	155.42	155.63

FILE 'CAPLUS' ENTERED AT 12:01:00 ON 03 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 1 Oct 2004 (20041001/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 14
L5 3 L4

=> d 15 1-3 bib hitstr

10/554,186

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:433750 CAPLUS
DN 141:7131
TI Preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for the treatment of cancer
IN Barnett, Stanley F.; Defeo-Jones, Deborah D.; Hartman, George D.; Huber, Hans E.; Stirdivant, Steven M.; Heimbrook, David C.
PA USA
SO U.S. Pat. Appl. Publ., 121 pp., which
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004102360	A1	20040527	US 2003-678565	20031003
PRAI US 2002-422312P	P	20021030		
US 2003-460911P	P	20030407		
OS MARPAT 141:7131				
IT 612847-15-1P	612847-16-2P	612847-17-3P		
612847-18-4P	612847-19-5P	612847-20-8P		
612848-78-9P	616873-13-3P	616873-19-9P		
616873-21-3P	616873-27-9P	616873-29-1P		
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)	(antitumor agent; preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for treatment of cancer)			
RN 612847-15-1	CAPLUS			
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(2-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)				

/ Structure 4 in file .gra /

RN 612847-16-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(2-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-15-1
CMF C33 H35 N5 O2

/ Structure 5 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 6 in file .gra /

RN 612847-17-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-indol-3-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA

10/554,186

INDEX NAME)

/ Structure 7 in file .gra /

RN 612847-18-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-indol-3-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-17-3
CMF C38 H34 N6 O2

/ Structure 8 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 9 in file .gra /

RN 612847-19-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-indol-3-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 10 in file .gra /

RN 612847-20-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-indol-3-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-19-5
CMF C38 H34 N6 O2

/ Structure 11 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 12 in file .gra /

RN 612848-78-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/554,186

/ Structure 13 in file .gra /

RN 616873-13-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-78-9
CMF C33 H35 N5 O2

/ Structure 14 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 15 in file .gra /

RN 616873-19-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-6-oxo-3-phenyl-5-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-18-8
CMF C36 H33 N5 O2

/ Structure 16 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 17 in file .gra /

RN 616873-21-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-20-2
CMF C33 H35 N5 O2

/ Structure 18 in file .gra /

CM 2

CRN 76-05-1

10/554,186

CMF C2 H F3 O2

/ Structure 19 in file .gra /

RN 616873-27-9 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-imidazol-4-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-26-8

CMF C33 H31 N7 O2

/ Structure 20 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 21 in file .gra /

RN 616873-29-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-(4,5-dihydro-6-methyl-5-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-28-0

CMF C30 H29 N5 O2

/ Structure 22 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 23 in file .gra /

10/554,186

LS ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:836759 CAPLUS

DN 139:350753

TI Preparation of 2,3-diphenylpyrazine derivatives as inhibitors of Akt activity for treating cancer

IN Duggan, Mark E.; Lindsley, Craig W.; Zhao, Zhijian

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 119 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003086279	A2	20031023	WO 2003-US10342	20030404
WO 2003086279	A3	20040108		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2002-370842P P 20020408

OS MARPAT 139:350753

IT 612847-15-1P 612847-16-2P 612847-17-3P
612847-18-4P 612847-19-5P 612847-20-8P
612847-21-9P 612847-22-0P 612847-23-1P
612847-24-2P 612847-25-3P 612847-26-4P
612848-78-9P 616873-13-3P 616873-14-4P
616873-15-5P 616873-16-6P 616873-17-7P
616873-18-8P 616873-19-9P 616873-20-2P
616873-21-3P 616873-22-4P 616873-23-5P
616873-24-6P 616873-25-7P 616873-26-8P
616873-27-9P 616873-28-0P 616873-29-1P
616873-30-4P 616873-31-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,3-diphenylpyrazine derivs. as inhibitors of Akt activity for treating cancer)

RN 612847-15-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(2-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

/ Structure 24 in file .gra /

RN 612847-16-2 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(2-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-15-1

CMF C33 H35 N5 O2

10/554,186

/ Structure 25 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 26 in file .gra /

RN 612847-17-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-indol-3-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 27 in file .gra /

RN 612847-18-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-indol-3-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-17-3
CMF C38 H34 N6 O2

/ Structure 28 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 29 in file .gra /

RN 612847-19-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-indol-3-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 30 in file .gra /

RN 612847-20-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-indol-3-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-19-5
CMF C38 H34 N6 O2

/ Structure 31 in file .gra /

10/554,186

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 32 in file .gra /

RN 612847-21-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-5-oxo-3-phenyl-6-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI)
(CA INDEX NAME)

/ Structure 33 in file .gra /

RN 612847-22-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-5-oxo-3-phenyl-6-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-21-9
CMF C36 H33 N5 O2

/ Structure 34 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 35 in file .gra /

RN 612847-23-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 36 in file .gra /

RN 612847-24-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-23-1
CMF C33 H35 N5 O2

/ Structure 37 in file .gra /

CM 2

10/554,186

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 38 in file .gra /

RN 612847-25-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-imidazol-4-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI)
(CA INDEX NAME)

/ Structure 39 in file .gra /

RN 612847-26-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-imidazol-4-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-25-3
CMF C33 H31 N7 O2

/ Structure 40 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 41 in file .gra /

RN 612848-78-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 42 in file .gra /

RN 616873-13-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-78-9
CMF C33 H35 N5 O2

/ Structure 43 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

10/554,186

/ Structure 44 in file .gra /

RN 616873-14-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(4,5-dihydro-5-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 45 in file .gra /

RN 616873-15-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(4,5-dihydro-5-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-14-4
CMF C29 H27 N5 O2

/ Structure 46 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 47 in file .gra /

RN 616873-16-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(1,6-dihydro-6-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 48 in file .gra /

RN 616873-17-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(1,6-dihydro-6-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-16-6
CMF C29 H27 N5 O2

/ Structure 49 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 50 in file .gra /

10/554,186

RN 616873-18-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-6-oxo-3-phenyl-5-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI)
(CA INDEX NAME)

/ Structure 51 in file .gra /

RN 616873-19-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-6-oxo-3-phenyl-5-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-18-8
CMF C36 H33 N5 O2

/ Structure 52 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 53 in file .gra /

RN 616873-20-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 54 in file .gra /

RN 616873-21-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-20-2
CMF C33 H35 N5 O2

/ Structure 55 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 56 in file .gra /

RN 616873-22-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(hydroxymethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/554,186

INDEX NAME)

/ Structure 57 in file .gra /

RN 616873-23-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(hydroxymethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 616873-22-4
CMF C30 H29 N5 O3

/ Structure 58 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 59 in file .gra /

RN 616873-24-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(hydroxymethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 60 in file .gra /

RN 616873-25-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(hydroxymethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 616873-24-6
CMF C30 H29 N5 O3

/ Structure 61 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 62 in file .gra /

RN 616873-26-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-imidazol-4-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/554,186

/ Structure 63 in file .gra /

RN 616873-27-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-imidazol-4-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-26-8
CMF C33 H31 N7 O2

/ Structure 64 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 65 in file .gra /

RN 616873-28-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(4,5-dihydro-6-methyl-5-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 66 in file .gra /

RN 616873-29-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(4,5-dihydro-6-methyl-5-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-28-0
CMF C30 H29 N5 O2

/ Structure 67 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 68 in file .gra /

RN 616873-30-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(1,6-dihydro-5-methyl-6-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 69 in file .gra /

RN 616873-31-5 CAPLUS

10/554,186

CN 2H-Benzimidazol-2-one, 1-[1-[[4-(1,6-dihydro-5-methyl-6-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-30-4
CMF C30 H29 N5 O2

/ Structure 70 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 71 in file .gra /

10/554,186

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:818232 CAPLUS
DN 139:323527
TI Preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer
IN Barnett, Stanley F.; Defeo-Jones, Deborah; Haskell, Kathleen M.; Huber, Hans E.; Nahas, Deborah D.; Lindsley, Craig W.; Zhao, Zhijian; Hartman, George D.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084473	A2	20031016	WO 2003-US10632	20030404
	WO 2003084473	A3	20040212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-370827P	P	20020408		
	US 2002-417202P	P	20021009		
IT	612847-16-2P	612847-18-4P	612847-20-8P		
	612847-22-0P	612847-24-2P	612847-26-4P		
	612848-79-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer)				
RN	612847-16-2	CAPLUS			
CN	2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(2-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)				
	CM 1				
CRN	612847-15-1				
CMF	C33 H35 N5 O2				

/ Structure 72 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 73 in file .gra /

RN 612847-18-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-indol-3-ylmethyl)-5-oxo-

10/554,186

3-phenylpyrazinyl]phenyl)methyl]-4-piperidinyl]-1,3-dihydro-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-17-3
CMF C38 H34 N6 O2

/ Structure 74 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 75 in file .gra /

RN 612847-20-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-indol-3-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl)methyl]-4-piperidinyl]-1,3-dihydro-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-19-5
CMF C38 H34 N6 O2

/ Structure 76 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 77 in file .gra /

RN 612847-22-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-5-oxo-3-phenyl-6-(phenylmethyl)pyrazinyl]phenyl)methyl]-4-piperidinyl]-1,3-dihydro-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-21-9
CMF C36 H33 N5 O2

/ Structure 78 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 79 in file .gra /

10/554,186

RN 612847-24-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-23-1
CMF C33 H35 N5 O2

/ Structure 80 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 81 in file .gra /

RN 612847-26-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-imidazol-4-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-25-3
CMF C33 H31 N7 O2

/ Structure 82 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

/ Structure 83 in file .gra /

RN 612848-79-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-78-9
CMF C33 H35 N5 O2

/ Structure 84 in file .gra /

CM 2

CRN 76-05-1
CMF C2 H F3 O2

10/554,186

/ Structure 85 in file .gra /

10/554, 186

STN INTERNATIONAL LOGOFF AT 12:01:24 ON 03 OCT 2004